Parkinson's Disease Research
Parkinson's disease (PD) is a degenerative disease of the central nervous system that often impairs motor skills, speech, and other functions. Symptoms of the disease include resting tremor, bradykinesia and rigidity. The primary symptoms are the result of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Symptoms of the disease appear once 50-80% of dopamine neurons have died. Parkinson's disease is both chronic and progressive.
Parkinson's Disease Research Products Targets
- Adenosine A2B Receptor (7)
- Adenosine A2A Receptor (11)
- Caspase (9)
- Bcl-2 Family (13)
- Voltage-gated Calcium Channel (CaV) (38)
- GABAB Receptor (28)
- Others (23)
- Cyclooxygenase (24)
- D4 Receptor (12)
- STIM-Orai Channel (4)
- Ryanodine Receptor (6)
- Hsp90 (10)
- Hsp70 (4)
- 5-HT7 Receptor (11)
- 5-HT6 Receptor (14)
- 5-ht5 Receptor (2)
- 5-HT4 Receptor (17)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- GABAA-ρ Receptor (8)
- GABAA Receptor (66)
- Nicotinic (α7) Receptor (25)
- Nicotinic (α4β2) Receptor (14)
- D3 Receptor (12)
- LRRK2 (4)
- Catechol O-Methyltransferase (3)
- Vesicular Monoamine Transporter (4)
- NMDA Receptor (87)
- Kainate Receptor (22)
- IP3 Receptor (2)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Trk Receptor (13)
- Trace Amine 1 Receptor (2)
- Adenosine A3 Receptor (8)
- Adenosine A1 Receptor (12)
- Monoamine Oxidase (10)
- M5 Receptor (2)
- M4 Receptor (3)
- M3 Receptor (4)
- M2 Receptor (5)
- M1 Receptor (8)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
- Protein Arginine Methyltransferase (2)
Products for Parkinson's Disease Research - Page 57
- Cat.No. Product Name Information/Activity
-
BCC5883
PDZ1 Domain inhibitor peptide
1315378-73-4
-
BCC6566
cis-ACPD
477331-06-9
-
BCC2894
H-D-Asp-OH
(-)-Aspartic acid is an endogenous NMDA receptor agonist.
-
BCC2881
H-Asp-OH
L-Aspartic acid is is an amino acid, shown to be a suitable prodrug for colon-specific drug deliverly.
-
BCC6571
L-Cysteinesulfinic acid
L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC50s of 3.92±0.03, 4.6±0.2, 3.9±0.2, 2.7±0.2, 4.0±0.2, and 3.94±0.08 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively.
-
BCC6013
GLYX 13
Rapastinel (GLYX-13) is an N-methyl-D-aspartate receptor (NMDAR) modulator that has characteristics of a glycine site partial agonist.
-
BCC6588
(R)-(+)-HA-966
(R)-(+)-HA-966 ((+)-HA-966) is a partial agonist/antagonist of glycine site of the N-methyl-D-aspartate (NMDA) receptor complex. (R)-(+)-HA-966 selectively blocks the activation of the mesolimbic dopamine system by amphetamine. (R)-(+)-HA-966 can cross the blood-brain barrier and has the potential for neuropathic and acute pain.
-
BCC6570
Homoquinolinic acid
490-75-5
-
BCC6591
Ibotenic acid
Ibotenic acid has agonist activity at both the N-methyl-D-aspartate (NMDA) and trans-ACPD or metabolotropic quisqualate (Qm) receptor sites.
-
BCC5896
MNI-caged-D-aspartate
845555-94-4


